

Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 6659 4333, 3980 4333, 2342 0500 / 501
F +91 40 6659 4320 / 3980 4320



October 28, 2022

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that US Food and Drug Administration (USFDA) today completed a Pre-Approval Inspection (PAI) at our manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. The inspection was conducted from 24th October 2022 to 28th October 2022. We have been issued a Form 483 with one observation. The observation is procedural in nature. The Company will address the observation within stipulated timelines.

This is for your information and records.

Thanking you,

Yours sincerely,

For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary &
Compliance Officer